APA (7th ed.) Citation

Lindholm, E. M., Krohn, M., Iadevaia, S., Kristian, A., Mills, G. B., Mælandsmo, G. M., & Engebraaten, O. (2014). Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations. Clinical cancer research, 20(2), 404-412. https://doi.org/10.1158/1078-0432.CCR-13-1865

Chicago Style (17th ed.) Citation

Lindholm, Evita M., Marit Krohn, Sergio Iadevaia, Alexandr Kristian, Gordon B. Mills, Gunhild M. Mælandsmo, and Olav Engebraaten. "Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations." Clinical Cancer Research 20, no. 2 (2014): 404-412. https://doi.org/10.1158/1078-0432.CCR-13-1865.

MLA (9th ed.) Citation

Lindholm, Evita M., et al. "Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations." Clinical Cancer Research, vol. 20, no. 2, 2014, pp. 404-412, https://doi.org/10.1158/1078-0432.CCR-13-1865.